Form 4: Gilead Sciences Executive Reports Stock Transaction
Insider Transaction (Form 4)
Dietmar Berger, Chief Medical Officer of Gilead Sciences, Inc., reported multiple transactions in common stock on September 10, 2026.
Summary
- Option exercise/conversion: acquired 533 Common Stock on September 10, 2026; holds 19,785 after (Direct).
- Tax/exercise-price withholding: disposed of 263 Common Stock at $144.81 ($38,085) on September 10, 2026; holds 19,522 after (Direct).
- Option exercise/conversion: disposed of 533 Restricted Stock Unit on September 10, 2026; holds 46,395 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Dietmar Berger — Officer (Chief Medical Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-10 | Option exercise/conversion | Common Stock | 533 | — | — | 19,785 |
| 2026-09-10 | Tax/exercise-price withholding | Common Stock | 263 | $145 | $38.1K | 19,522 |
| 2026-09-10 | Option exercise/conversion | Restricted Stock Unit | 533 | — | — | 46,395 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-10 | Option exercise/conversion (533 shares) |
| 2026-09-10 | Tax/exercise-price withholding (263 shares) |
| 2026-09-10 | Option exercise/conversion (533 shares) |
Keywords
insider transaction, Form 4, GILD, GILEAD SCIENCES, INC., neutral, Dietmar Berger
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.